Cellogen Therapeutics | Advanced CAR T-Cell & Gene Therapy
Home > About Us

About Cellogen Therapeutics

We at Cellogen Therapeutics use advanced cellular engineering methods and gene therapy-based approaches to find curative treatment for various hematological malignancies, solid tumors and hemoglobinopathies.

We have conceptualised and designed state-of-the-arts third and fourth generation CAR constructs (CAR T-cell therapies)  for Blood cancers such as leukaemia, lymphoma. We  have also developed genetic therapies  for Beta-Thalassemia and sickle cell disease, the two most common debilitating blood disorders.

Over the last decade, the impressive clinical outcome of cell and gene-based therapies has given a new hope for patients suffering from life-threatening diseases. Cellular and gene therapies have transformed the therapeutic landscape by providing long-lasting and permanent cure. However, these therapeutic modalities are currently expensive and limited to a few countries. Our vision is to make these revolutionary therapies available to masses, particularly for the patients in India where the majority of the patients cannot afford the cost. We will provide a convenient and cost-effective solution by indigenously manufacturing these therapeutic modalities.

Our Journey

Established in 8
June 2021

With the aim of developing modern treatment modalities for various cancers and blood disorders

Collaboration with CSIR- IGIB
December 2021

Signed an MoU with CSIR-IGIB to collaborate on pre-clinical research

Collaboration with
RCB, DBT

September 2023 Signed an MoU with CSIR-RCB to collaborate on in-vivo pre-clinical research

Collaboration with IICB,
Kolkata August 2023

September 2023 Partnered with the laboratory for pre-clinical research work.

Supported by
Natco January 2024

Received series 1A funding from NATCO pharmaceuticals

Collaboration with
CMC Vellore May 2024

Initiated the process for clinical trials of CAR T Cells.

Meet Our Team

Our team thrives on collaboration, courage, and a shared vision. By tackling challenges head-on and taking measurable strides toward our goals, we aim to pioneer transformative, gene-based therapies that redefine the future of medicine.

Dr. Gaurav Kharya

Co-Founder, Cellogen Therapeutics

Dr. Gaurav Kharya is a renowned expert in blood disorders, immunological diseases, and pediatric cancers, specialising in improving hematopoietic stem cell transplant outcomes using alternative donors. At Cellogen Therapeutics, he spearheads efforts to develop India’s own cell and gene therapy products, including CAR T cell therapy and gene manipulation strategies, to revolutionise treatments for cancers and blood disorders like thalassemia and sickle cell anemia. Renowned for his clinical expertise and patient-first approach, Dr. Kharya is dedicated to advancing accessible, cutting-edge therapies, positioning India as a global leader in cell and gene therapy innovation.


Our Associates & Partners

We collaborate with leading research institutes and healthcare pioneers to transform treatment possibilities for cancers